Famciclovir and valaciclovir differ in the prevention of herpes simplex virus type 1 latency in mice: A quantitative study

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 7, 1998, Pages 1555-1562

  Thackray, Alana M ^a   Field, Hugh J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FAMCICLOVIR; VALACICLOVIR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HERPES SIMPLEX VIRUS 1; INFECTION PREVENTION; INTRAPERITONEAL DRUG ADMINISTRATION; LATENT PERIOD; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; VIRUS DETECTION; VIRUS INHIBITION;

EID: 0031862250     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.7.1555     Document Type: Article

References (29)

1. Arthur, J., S. Efstathiou, and A. Simmons. 1993. Intranuclear foci containing low abundance herpes simplex virus latency-associated transcripts visualized by non-isotopic in situ hybridization. J. Gen. Virol. 74:1363-1370.
2. Bacon, T. H., and B. A. Howard. 1996. Further characterization of the potent and prolonged inhibition of herpes simplex virus replication in human cell lines by penciclovir. Antivir. Chem. Chemother. 7:128-137.
3. Blyth, W. A., D. A. Harbour, and T. J. Hill. 1980. Effect of acyclovir on recurrence of herpes simplex skin lesions in mice. J. Gen. Virol. 48:417-419.
4. Boyd, M. R., T. H. Bacon, D. Sutton, and M. Cole. 1987. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob. Agents Chemother. 31:1238-1242.
5. Boyd, M. R., T. H. Bacon, and D. Sutton. 1988. Antiherpes activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in animals. Antimicrob. Agents Chemother. 32:358-363.
6. Boyd, M. R., S. Safrin, and E. R. Kern. 1993. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antivir. Chem. Chemother. 4:3-11.
7. Earnshaw, D. L., T. H. Bacon, S. J. Darlison, K. Edmonds, R. M. Perkins, and R. A. Vere Hodge. 1992. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob. Agents Chemother. 36:2747-2757.
8. Field, H. J. 1990. Famciclovir - origins, progress and prospects. Exp. Opin. Invest. Drugs 5:925-938.
9. Field, H. J., S. E. Bell, G. B. Elion, A. A. Nash, and P. Wildy. 1979. Effect of acycloguanosine treatment on acute and latent herpes simplex infections in mice. Antimicrob. Agents Chemother. 15:554-561.
10. Field, H. J., and E. De Clercq. 1981. Effects of oral treatment with acyclovir and bromovinyldeoxyuridine on the establishment and maintenance of latent herpes simplex virus infection in mice. J. Gen. Virol. 56:259-265.
11. Field, H. J., D. Tewari, D. Sutton, and A. M. Thackray. 1995. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. Antimicrob. Agents Chemother. 39: 1114-1119.
12. Field, H. J., and A. M. Thackray. 1996. Valaciclovir and famciclovir - differences between two similar guanosine analogue prodrugs emerge from laboratory models. Int. Antivir. News 4:23-27.
13. Fraser, N., and T. Valyi-Nagy. 1993. Viral, neuronal, and immune factors which may influence herpes simplex virus (HSV) latency and reactivation. Microb. Pathog. 15:83-91.
14. Goldthorpe, S. E., M. R. Boyd, and H. J. Field. 1992. Effects of penciclovir and famciclovir in a murine model of encephalitis induced by intranasal inoculation of herpes simplex virus type 1. Antivir. Chem. Chemother. 3:37-47.
15. Hill, T. J., H. J. Field, and W. A. Blyth. 1975. Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease. J. Gen. Virol. 28:341-353.
16. Kennedy, P. G. E., R. P. Lisak, and M. C. Raff. 1980. Cell type-specific markers for human glial and neuronal cells in culture. Lab. Invest. 43:342-351.
17. Klein, R. J., A. E. Friedman-Kien, and P. B. Yellin. 1978. Orofacial herpes simplex virus infection in hairless mice; latent virus in trigeminal ganglia after topical antiviral treatment. Infect. Immun. 20:130-135.
18. Klein, R. J., A. E. Friedman-Kien, and E. de Stefano. 1979. Latent herpes simplex virus infection in sensory ganglia of hairless mice prevented by acycloguanosine. Antimicrob. Agents Chemother. 15:723-729.
19. Leib, D. A., D. M. Coen, C. L. Bogard, K. A. Hicks, D. R. Yager, D. M. Knipe, K. L. Tyler, and P. A. Schaffer. 1989. Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J. Virol. 63:759-768.
20. Park, N.-H., D. Pavan-Langston, and S. L. McLean. 1979. Acyclovir in oral and ganglionic herpes simplex virus infections. J. Infect. Dis. 140:802-806.
21. Pavan-Langston, D., N. H. Park, and J. H. Lass. 1979. Herpetic ganglionic latency. Aciclovir and vidarabine therapy. Arch. Ophthalmol. 97:1508-1510.
22. Stevens, J. G., and M. L. Cook. 1971. Latent herpes simplex virus in spinal ganglia of mice. Science 173:843-845.
23. Sutton, D., and M. R. Boyd. 1993. Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. Antimicrob. Agents Chemother. 37:642-645.
24. Thackray, A. M., and H. J. Field. 1996. Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. J. Infect. Dis. 173:291-299.
25. Thackray, A. M., and H. J. Field. 1996. Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Antimicrob. Agents Chemother. 40:846-851.
26. 25a. Thackray, A. M., and H. J. Field. Unpublished data.
27. Vere Hodge, R. A., and Y.-C. Cheng. 1993. The mode of action of penciclovir. Antivir. Chem. Chemother. 4:13-24.
28. Vere Hodge, R. A., and R. M. Perkins. 1989. Mode of action of 9-(4-hydroxy3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob. Agents Chemother. 33:223-229.
29. Wildy, P., H. J. Field, and A. A. Nash. 1982. Classical herpes latency revisited, p. 133-167. In Virus persistence, Symposium 33, Society for General Microbiology). Cambridge University Press, Cambridge, United Kingdom.